Microrna-22 Coordinates Asthma and Pulmonary Emphysema Through Histone Deacetylase 4

Wen Lu,David B. Corry,Farrah Kheradmand
DOI: https://doi.org/10.1016/j.jaci.2014.12.1877
IF: 14.29
2015-01-01
Journal of Allergy and Clinical Immunology
Abstract:As a new layer of gene regulators involved in most biological processes, microRNAs (miRNAs) haven't been intensively studied in asthma and emphysema. Our goal is to study pathogenic roles and therapeutic potentials of miR-22 in both diseases. In the experimental emphysema model, wildtype and miR-22-/- mice were exposed to 4 month cigarette smoke. In the experimental allergic asthma model, mice were exposed to Aspergillus niger for 2 weeks. MiR-22-/- mice are highly resistant to cigarette smoke induced emphysema and fungus-induced allergic asthma. We further pinpointed miR-22 expressed in antigen presenting cell (APC) contributes to disease pathogenesis using conditional genetic knockout mice and adoptive transfer experiments. MiR-22 is upregulated in asthmatic and emphysematous lung APCs. MiR-22 deficient APCs express less CD40, CD86 on their surface and secret less IL-1β, IL-6, accompanied by impaired ability to induce T helper cell 17 (TH17) response. Mechanistically, miR-22 inhibits one of its target gene, histone deacetylase 4 (HDAC4) in APCs, which acts as a molecule 'brake' to APC activation. HDAC4 deficient APCs are hypersensitive to lipopolysaccharide (LPS) or antagonistic CD40 stimuli. Mice with HDAC4 conditional deletion in CD11c cells are more susceptible to emphysema. Moreover, intranasal administration of miR-22 sponge locked nucleic acid (LNA) is able to restore HDAC4's level in lung APCs and reverse fully developed emphysema and asthma in mice. MiR-22 is a master regulator of antigen presenting cell activation and thereby controls asthma and emphysema pathogenesis. Direct targeting miR-22 in lung is a promising strategy to cure emphysema and asthma.
What problem does this paper attempt to address?